Jeonjinbio Co., Ltd. (KOSDAQ:110020)
South Korea
· Delayed Price · Currency is KRW 2,405.00
+5.00 (0.21%)
Last updated: Mar 26, 2025
Jeonjinbio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 19,273 | 15,681 | 7,794 | 3,214 | 3,867 | Upgrade
|
| Other Revenue | -0 | - | -0 | - | - | Upgrade
|
| Revenue | 19,273 | 15,681 | 7,794 | 3,214 | 3,867 | Upgrade
|
| Revenue Growth (YoY) | 22.91% | 101.18% | 142.48% | -16.87% | -2.08% | Upgrade
|
| Cost of Revenue | 13,271 | 10,861 | 5,877 | 1,898 | 1,698 | Upgrade
|
| Gross Profit | 6,002 | 4,820 | 1,917 | 1,316 | 2,168 | Upgrade
|
| Selling, General & Admin | 3,359 | 3,937 | 4,261 | 3,716 | 3,399 | Upgrade
|
| Research & Development | 361.75 | 447.75 | 421.95 | 363.84 | 344.95 | Upgrade
|
| Other Operating Expenses | 142.94 | 134.69 | 111.8 | 82.76 | 64.93 | Upgrade
|
| Operating Expenses | 4,843 | 6,065 | 5,094 | 4,346 | 4,037 | Upgrade
|
| Operating Income | 1,158 | -1,245 | -3,177 | -3,030 | -1,869 | Upgrade
|
| Interest Expense | -432.26 | -1,195 | -2,035 | -865.67 | -515.62 | Upgrade
|
| Interest & Investment Income | 98.86 | 115.08 | 158.71 | 44.12 | 22.51 | Upgrade
|
| Currency Exchange Gain (Loss) | 6.35 | 2.71 | -25.17 | -8.62 | -11.57 | Upgrade
|
| Other Non Operating Income (Expenses) | 4,226 | -3,564 | 1,832 | 1,755 | -742.15 | Upgrade
|
| EBT Excluding Unusual Items | 5,057 | -5,886 | -3,246 | -2,105 | -3,116 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | -16.64 | Upgrade
|
| Gain (Loss) on Sale of Assets | -456.58 | 9.94 | - | -2.91 | -5.63 | Upgrade
|
| Asset Writedown | -254.15 | -636.91 | - | - | - | Upgrade
|
| Other Unusual Items | - | 73.29 | 91.69 | - | -280.13 | Upgrade
|
| Pretax Income | 4,346 | -6,440 | -3,154 | -2,108 | -3,418 | Upgrade
|
| Net Income | 4,346 | -6,440 | -3,154 | -2,108 | -3,418 | Upgrade
|
| Net Income to Common | 4,346 | -6,440 | -3,154 | -2,108 | -3,418 | Upgrade
|
| Shares Outstanding (Basic) | 9 | 7 | 7 | 6 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 7 | 7 | 6 | 5 | Upgrade
|
| Shares Change (YoY) | 18.14% | 10.66% | 6.17% | 27.16% | 2.69% | Upgrade
|
| EPS (Basic) | 505.00 | -884.00 | -479.16 | -340.00 | -701.00 | Upgrade
|
| EPS (Diluted) | 505.00 | -884.00 | -479.16 | -340.00 | -701.00 | Upgrade
|
| Free Cash Flow | 2,616 | -960.95 | -5,705 | -4,232 | -8,109 | Upgrade
|
| Free Cash Flow Per Share | 303.93 | -131.91 | -866.55 | -682.57 | -1662.96 | Upgrade
|
| Gross Margin | 31.14% | 30.74% | 24.59% | 40.94% | 56.08% | Upgrade
|
| Operating Margin | 6.01% | -7.94% | -40.77% | -94.26% | -48.34% | Upgrade
|
| Profit Margin | 22.55% | -41.07% | -40.47% | -65.59% | -88.40% | Upgrade
|
| Free Cash Flow Margin | 13.57% | -6.13% | -73.19% | -131.67% | -209.71% | Upgrade
|
| EBITDA | 2,500 | 590.48 | -1,785 | -2,663 | -1,429 | Upgrade
|
| EBITDA Margin | 12.97% | 3.77% | -22.90% | -82.84% | -36.97% | Upgrade
|
| D&A For EBITDA | 1,342 | 1,835 | 1,392 | 367.09 | 439.62 | Upgrade
|
| EBIT | 1,158 | -1,245 | -3,177 | -3,030 | -1,869 | Upgrade
|
| EBIT Margin | 6.01% | -7.94% | -40.77% | -94.26% | -48.34% | Upgrade
|
| Advertising Expenses | 94.99 | 219.26 | 164.76 | 374.4 | 301.25 | Upgrade
|
Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.